1910

The page describes an AI model for blood-brain barrier (BBB) prediction of small molecules, covering beyond-rule-of-5 (bRo5) chemical space and stereochemistry for small-molecule CNS therapeutics.

A Multimodal AI Model for Macrocyclic Peptide Design: Predictive & Generative Modules for De Novo Design & Lead Optimization

1910’s ITO platform combines causal biology, multimodal data, federated learning, and lab-in-a-loop automation to deliver small and large molecule drug candidates faster and more reliably than traditional methods.

1910’s ITO platform combines causal biology, multimodal data, federated learning, and lab-in-a-loop automation to deliver small and large molecule drug candidates faster and more reliably than traditional methods.

The page presents research, white papers, and scientific analyses from 1910, including data on the ITO platform and its impact on transparent, modality-agnostic drug discovery.

1910 shares breakthroughs, press releases, and industry coverage about its work in transparent AI-driven drug discovery.

1910's press announcements cover partnerships, milestones, and its work to democratize AI for pharma.

The page features 1910’s breakthroughs, press releases, and industry coverage. 1910 advances transparent AI-driven drug discovery.

1910 is hiring to build infrastructure for drug discovery across small, large, and peptide modalities.

1910 is hiring to build infrastructure for drug discovery across small, large, and peptide modalities.

1910 describes its mission, leadership, ecosystem partnerships, and wet lab and AI infrastructure for pharma companies building AI capabilities.

The page covers 1910’s mission, leadership, and ecosystem partnerships. Its infrastructure combines wet lab and AI to help pharma companies build AI capabilities.

1910 offers AI drug discovery solutions through a transparent, modality-agnostic platform for pharma organizations.

1910 offers AI drug discovery solutions through a transparent, modality-agnostic platform for pharma organizations.

1910's ITO platform integrates wet lab, computational, and proxy data to support drug discovery for undruggable targets.

1910 provides multimodal, modality-agnostic AI infrastructure for pharma. Its ITO platform integrates wet lab, computational, and proxy data.

1910 publishes PEGASUS, a multimodal AI model that learns rules for designing cell-permeable macrocyclic peptides. The model enables access to traditionally difficult intracellular targets.

Jan 2026 · Genetic Engineering & Biotechnology NewsNews article

1910 Genetics launches CANDID-CNS, an attentive graph neural network that predicts blood-brain barrier permeability and the distribution of small-molecule drug candidates. The company says the model achieves an 83% success rate, compared with 64% for the industry-standard CNS-MPO score on this task.

Oct 2024 · Business WireNews article

GitHubRepository owner

Microsoft and 1910 Genetics announce a five-year commercial agreement to combine 1910’s multimodal AI platform with Microsoft Azure Quantum Elements. The companies describe the collaboration as building infrastructure for drug discovery and development using AI and high-performance computing, with the goal of accelerating pharmaceutical research and development productivity.

Feb 2024 · 1910 Press Release via Microsoft Azure BlogNews article